Cambrex has begun construction of a $120m expansion at its Charles City pharmaceutical manufacturing plant in Iowa. The project will add 160,000 litres of manufacturing capacity, taking the facility’s reported total towards one million litres. Cambrex intends to use the new equipment for the development and commercial production of small-molecule active pharmaceutical ingredients and synthetic peptides, with completion scheduled for the fourth quarter of 2028.
A groundbreaking ceremony on 29 October marked the next stage of an investment first outlined in 2025. The site is also celebrating 100 years of operation and already serves customers from early process development through commercial manufacturing. Existing laboratories, quality systems and regulated production operations provide an established framework for the additional capacity. The construction programme will still need to accommodate ongoing activity at the plant and introduce new equipment through installation, commissioning and qualification.
The 160,000-litre figure describes added process volume rather than an annual quantity of finished pharmaceutical ingredients. Reactors of a given size can deliver very different outputs depending on the chemistry, batch concentration, process duration, cleaning and downstream recovery. Equipment availability and quality testing further shape the number of batches that can be released. The expansion’s production effect will therefore depend on the mixture of customer programmes scheduled into the new facilities, rather than the installed vessel volume alone.
Small-molecule API manufacturing commonly involves a sequence of reactions, separations, crystallisation and drying operations. Industrial scale-up requires attention to heat transfer, mixing, addition rates and the removal of unwanted reaction by-products. Conditions that work in a laboratory flask do not automatically reproduce at several thousand litres because fluid movement and the relationship between vessel surface area and liquid volume change. Process development and engineering must establish operating limits that deliver the required chemistry consistently in larger equipment.
Earlier project engineering identified large and mid-scale reactors and Hastelloy agitated filter dryers among the equipment under consideration for Charles City. Hastelloy’s corrosion resistance can be important for demanding chemical processes, while agitated filter dryers allow solids to be separated from liquids and dried within a controlled vessel. These operations connect reactor output to the subsequent handling of the active ingredient. As construction progresses, process equipment, utility capacity and contained transfers must be designed to work together rather than assessed as isolated additions.
Synthetic peptide production adds requirements for repeated chemical steps and purification of the specified molecular sequence. The number of processing stages, solvent consumption and analytical checks can influence the usable capacity of production equipment. A contract manufacturer increasing scale must also maintain control of impurities and demonstrate consistent product identity and quality across batches. The new Charles City facilities are intended to serve these programmes alongside conventional small-molecule API manufacture.
Charles City’s manufacturing capabilities also extend to highly potent ingredients and controlled substances, which require additional containment and procedural controls. Personnel protection and the avoidance of cross-contamination have to be considered in equipment design, material transfers, cleaning and maintenance. Bringing new suites into a regulated facility therefore involves both physical construction and qualification of the systems that will control production. A completed building does not on its own establish that every proposed drug substance can immediately be manufactured at commercial scale.
Cambrex had previously described both the investment and its engineering preparation, so the October milestone is the start of construction at the existing factory. The company’s latest figures specify an additional 160,000 litres and a total approaching one million litres. The planned completion date remains the fourth quarter of 2028, when equipment installation and the relevant qualification work are expected to have progressed to the point of supporting the intended manufacturing activities.
As a contract development and manufacturing organisation, Cambrex must allocate plant time to products with different batch processes and quality requirements. A new suite can relieve a constraint only when supporting operations — from material transfer and solvent management to filtration, drying, testing and storage — can accommodate it. The expansion therefore combines additional process vessels with the infrastructure and operating systems needed for regulated pharmaceutical production.
Construction at Charles City will be followed by equipment installation, commissioning and qualification before the new capacity enters normal service. Cambrex is targeting the fourth quarter of 2028 for completion. The enlarged plant will provide further flexibility for API and synthetic peptide programmes progressing from development into commercial supply, with actual output determined by each product’s process and production schedule.
